Bloomberg Podcasts
@bloombergpodcasts·503K subscribers·32.4K videos
Lilly to Buy Psychedelic Firm AtaiBeckley for Up to $3.8 Billion
Posted
July 16, 2026
Views
537
Likes
14
Comments
1
Engagement
July 16, 2026
537
14
1
2.79%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
3:21Now PlayingSam Fazeli, Bloomberg Intelligence, Director of Research: Healthcare, Defence, Industrials & Autos, joined Bloomberg's Paul Sweeney and Scarlet Fu to dissect the latest in biotech sector, specifically Lilly going psychedelic and Merck attacking cholesterol.
Eli Lilly & Co. agreed to buy AtaiBeckley Inc. for as much as $3.8 billion, underscoring growing interest from large drugmakers in the once-fringe area of psychedelic medicine.
Lilly will pay $6.75 a share in cash plus as much as another $2.50 a share if drug-development milestones are met, according to a statement Thursday. The base price is 26% above where AtaiBeckley shares closed Wednesday. The announcement confirms a report by Bloomberg News that the companies were nearing a deal.
--------
Watch Bloomberg Radio LIVE on YouTube
Weekdays 7am-6pm ET
Saturday & Sunday 7am-10am ET
Follow us on X
Subscribe to our Podcasts:
Bloomberg Daybreak
Bloomberg Surveillance
Bloomberg Intelligence
Balance of Power
Bloomberg Businessweek
Listen on Apple CarPlay and Android Auto with the Bloomberg Business app:
Apple CarPlay
Android Auto
Visit our YouTube channels:
Bloomberg Podcasts
Bloomberg Television
Bloomberg Originals
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
